Hydroxyzine 50 mg QID PRN for Anxiety
Hydroxyzine 50 mg four times daily PRN (up to 200 mg/day) is appropriate and FDA-approved for anxiety, though you should start elderly patients at lower doses and monitor for QT prolongation in at-risk patients. 1
FDA-Approved Dosing
The FDA label explicitly states that for symptomatic relief of anxiety and tension associated with psychoneurosis, the approved adult dose is 50 to 100 mg four times daily (QID) 1. Your proposed regimen of 50 mg QID PRN (maximum 200 mg/day) falls within this approved range.
Key Prescribing Considerations
Efficacy Evidence
- Hydroxyzine 50 mg/day demonstrated statistically significant anxiolytic effects over placebo starting from week 1, with sustained efficacy through 4 weeks and no rebound anxiety upon abrupt discontinuation 2
- A 3-month trial confirmed maintained efficacy at 50 mg/day with comparable results to benzodiazepines (bromazepam 6 mg/day) 3
- The drug showed particular effectiveness on cognitive components of anxiety 4
Critical Safety Warnings (FDA Label)
QT Prolongation Risk 1:
- Use with caution in patients with:
- Pre-existing heart disease or electrolyte imbalances
- Congenital long QT syndrome or family history
- Recent MI, uncompensated heart failure, or bradyarrhythmias
- Concomitant use of QT-prolonging drugs (citalopram, fluoxetine, azithromycin, antipsychotics, methadone)
CNS Depression 1:
- Warn patients about drowsiness affecting driving/machinery operation
- Reduce doses of concomitant CNS depressants (narcotics, barbiturates, alcohol)
AGEP (Acute Generalized Exanthematous Pustulosis) 1:
- Discontinue immediately if fever with pustular rash develops
- Do not rechallenge; avoid cetirizine/levocetirizine due to cross-sensitivity
Geriatric Dosing Adjustment
Start elderly patients at the low end of the dosing range 1. The FDA specifically warns that sedating drugs cause confusion and oversedation in elderly patients due to decreased renal/hepatic function. Consider starting at 25 mg TID-QID rather than 50 mg QID.
Common Pitfalls to Avoid
Drowsiness is transient: The most common side effect (28% vs 14% placebo) typically appears in week 1 and progressively diminishes 2. Don't prematurely discontinue.
No dependency or withdrawal: Unlike benzodiazepines, hydroxyzine shows no evidence of dependency, and abrupt discontinuation causes no withdrawal symptoms 4, 2
Drug interactions: Screen for QT-prolonging medications before prescribing, particularly SSRIs (citalopram, fluoxetine), macrolide antibiotics, and antipsychotics 1
Practical Implementation
- PRN dosing is appropriate: While most studies used fixed daily dosing, the FDA label supports PRN use, and the lack of dependency makes this safer than benzodiazepine PRN regimens
- Monitor response: Efficacy should be apparent within the first week 2
- Maximum daily dose: Do not exceed 200 mg/day (your proposed 50 mg QID maximum)
- Baseline screening: Obtain ECG in patients with cardiac risk factors before initiating therapy